Renvistobart

HAYWARD, CA, USA I November 05, 2024 I Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, (DZ) versus zimberelimab (Z) or chemotherapy in patients with front-line locally advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without the presence of any tumor genomic aberration or driver mutation for which a targeted therapy is approved. This study was conducted in partnership with Gilead Sciences. These results will be presented on November 8 in a late-breaking poster session at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting by Melissa L. Johnson, M.D., Director of the Lung Cancer Research Program, Sarah Cannon Research Institute, and investigator for the ARC-10 study. “Domvanalimab plus zimberelimab demonstrated a meaningful improvement in overall survival compared to zimberelimab alone, with a 36% reduction in risk of death and a median overall survival that will exceed two years,” said Melissa L. Johnson, M.D. “These data provide further evidence that co-inhibiting the TIGIT and PD-1 pathways may result in a greater therapeutic benefit over inhibition of the PD-1 pathway alone.” “These are the first results demonstrating an improvement in overall survival reported for domvanalimab and zimberelimab,” said Dimitry Nuyten, M.D., Ph.D., chief medical officer of Arcus. “They add to the growing body of evidence that domvanalimab, an Fc-silent anti-TIGIT antibody, may have a differentiated efficacy, safety and tolerability profile relative to published data from studies with Fc-enabled anti-TIGIT antibodies.” At the time of data cutoff (DCO, May 17, 2024), 98 patients were randomized and 95 received treatment in Part 1 of the study. The median follow-up was 24.5 months, and as of the DCO, 22 patients remained on treatment (DZ, n=11; Z, n=10; chemo, n=1). Patient baseline demographics were generally balanced across the arms, with a slight imbalance of more patients with adenocarcinoma, ECOG status 0, and brain metastasis favoring the chemotherapy arm. A summary of efficacy results is below. DZ and Z were generally well tolerated with no new safety concerns at the time of DCO. Treatment-related adverse events (TRAEs) leading to treatment discontinuation were higher for chemotherapy (23.5%) than for DZ (10.5%) and Z (7.5%). Infusion-related reactions were low (DZ, 7.9%; Z, 2.5%; chemotherapy, 0%). Grade ≥3 TRAEs were higher for chemotherapy (47.1%) than for DZ (21.1%) or Z (15.0%). TRAEs leading to death were lower for DZ (2.6%; n=1 sudden death) vs Z (10.0%; n=1 each sudden death, acute kidney injury, acute myocardial infarction, intestinal perforation) or chemotherapy (11.8%; n=1 each febrile neutropenia, ischemic stroke). Investors may dial into the earnings conference call at +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 940081, on Wednesday, Nov. 6, 2024, at 2:00 PM PT / 5:00 PM ET. Participants may also register for the call online using this link: https://www.netroadshow.com/events/login?show=4818aee3&confId=72838 . To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com . A replay will be available following the live event. About the ARC-10 Study ARC-10 was initially initiated and conducted as a randomized Phase 3 trial; the protocol was subsequently amended to evaluate domvanalimab plus zimberelimab versus pembrolizumab (part 2). Part 1 of the ARC-10 study is a multicenter, randomized, open-label study for patients with front-line locally advanced or metastatic squamous or non-squamous NSCLC with PD-L1 TPS ≥50% without the presence of any tumor genomic aberration or driver mutation for which a targeted therapy is approved. The study randomized patients 2:2:1 across the three study arms to receive every three weeks: (1) 15 mg/kg of domvanalimab plus 360 mg/kg of zimberelimab, (2) 360 mg/kg of zimberelimab or (3) platinum doublet chemotherapy in countries where anti-PD-(L)1 monotherapy was not yet standard of care. The primary endpoint was PFS per Response Evaluation Criteria in Solid Tumors (RECIST 1.1). The secondary endpoints were OS, confirmed ORR and safety. About Domvanalimab Domvanalimab is the most clinically advanced Fc-silent investigational monoclonal antibody that was specifically designed with Fc-silent properties to block and bind to the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), a checkpoint receptor on immune cells that acts as a brake on the anticancer immune response. By binding to TIGIT with Fc-silent properties, domvanalimab is believed to work by freeing up immune-activating pathways and activating immune cells to attack and kill cancer cells without depleting the peripheral regulatory T cells important in avoiding immune-related toxicity. Combined inhibition of both TIGIT and programmed cell death protein-1 (PD-1) is believed to significantly enhance immune cell activation, as these checkpoint receptors play distinct, complementary roles in anti-tumor activity. Domvanalimab is being evaluated in combination with anti-PD-1 monoclonal antibodies, including zimberelimab, as well as other investigational cancer immunotherapies and A2a/A2b adenosine receptor antagonist etrumadenant, in multiple ongoing and planned early and late-stage clinical studies in various tumor types. About Zimberelimab Zimberelimab is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody that binds PD-1, with the goal of restoring the anti-tumor activity of T cells. Zimberelimab has demonstrated high affinity, selectivity and potency in various tumor types. Zimberelimab is being evaluated in the U.S. and globally as a foundational anti-PD-1 treatment option in multiple ongoing and planned early and late-stage clinical studies in combination with other immunotherapies, including investigational Fc-silent anti-TIGIT monoclonal antibody domvanalimab and A2a/A2b adenosine receptor antagonist etrumadenant. Guangzhou Gloria Biosciences Co. Ltd., which holds commercialization rights for zimberelimab in greater China, has obtained approval for zimberelimab for the treatment of recurrent or metastatic cervical cancer and for relapsed or refractory classical Hodgkin’s lymphoma. Zimberelimab is not approved for any use in the U.S. or other regions outside of China. Gloria conducts its development and commercialization activities independent of Arcus and Gilead. Domvanalimab and zimberelimab are investigational molecules. Arcus and Gilead have not received approval from any regulatory authority for any commercial use globally, and their safety and efficacy for the treatment of lung cancer have not been established. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39, and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com . SOURCE: Arcus Biosciences

In a landscape marred by high-profile setbacks for TIGIT inhibitors, Arcus Biosciences has emerged with a potential bright spot. The biotech is reporting positive overall survival (OS) and progression-free survival (PFS) data from a now-discontinued study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody partnered with Gilead Sciences, in combination with the PD-1 inhibitor zimberelimab.Results from the ARC-10 study, shared at the Society for Immunotherapy of Cancer (SITC) annual meeting this week, come as the TIGIT inhibitor class struggles to deliver on its promise. Fizzling enthusiasm for the approach follows clinical failures for Roche's tiragolumab, while Merck & Co. has scrapped studies of vibostolimab in both lung cancer and melanoma. See – Spotlight On: Another vibostolimab setback sets somber tone for any prevailing TIGIT expectations.However, new data from iTEOS Therapeutics and GSK reignited hope in September, with the addition of TIGIT inhibitor belrestotug and the latter's PD-1 inhibitor Jemperli (dostarlimab) showing promising response rates in lung cancer. For more, read KOL Views Q&A: New TIGIT, LAG-3 data suggest transformative potential still on table for at least one in NSCLC.ARC-10 began as a randomised Phase III trial and was later amended to compare domvanalimab plus zimberelimab against Merck's Keytruda (pembrolizumab) in a second part of the study. The first part of the trial, whose results were reported at the SITC meeting, evaluated domvanalimab plus zimberelimab, zimberelimab alone, or platinum doublet chemotherapy in countries where anti-PD-(L)1 monotherapy was not yet standard of care.Arcus and Gilead decided earlier this year to discontinue enrollment in ARC-10, citing a "strategic prioritisation" in favour of advancing two other late-stage trials, STAR-121 and STAR-221, in lung and gastrointestinal cancers, respectively.The data presented at the SITC conference focused on patients with advanced or metastatic NSCLC who had a high level of the PD-L1 marker (TPS ≥50%) and no genetic mutations that could be treated with targeted therapies. As of the May 17 data cutoff, 95 participants had received treatment in the first part of the study.OS benefit of 36%According to Arcus, pairing domvanalimab with zimberelimab led to a 36% reduction in the risk of death compared to zimberelimab alone. Median OS for the combination arm was not reached, while the zimberelimab and chemotherapy arms reached median OS of 24.4 months and 11.9 months. respectively. PFS was also improved with the combo, at 11.5 months versus 6.2 months for zimberelimab and 9.6 months for chemotherapy."These are the first results demonstrating an improvement in overall survival reported for domvanalimab and zimberelimab," said Dimitry Nuyten, chief medical officer of Arcus. "They add to the growing body of evidence that domvanalimab…may have a differentiated efficacy, safety and tolerability profile relative to published data from studies with Fc-enabled anti-TIGIT antibodies."Regarding safety, the combination of domvanalimab plus zimberelimab was also generally well tolerated, with lower rates of treatment-related adverse events (TRAEs) leading to discontinuation compared to chemotherapy. Patients were more likely to stop treatment due to side effects with chemotherapy (23.5%) than with the combination (10.5%) or zimberelimab alone (7.5%).Grade ≥3 TRAEs were also more common with chemotherapy (47.1%) than with the combination (21.1%) or zimberelimab monotherapy (15%). Deaths related to treatment were lower in the combo arm (2.6%, one case of sudden death) compared to zimberelimab (10%, various causes) and chemotherapy (11.8%, various causes).